SLS SELLAS Life Sciences Group, Inc. stock chart & analysis
Conviction 36HealthcareScan · Fri, Nov 6, 2026SELLAS Life Sciences Group, Inc. (SLS) closed at $8.42 (+6.85%) on Nov 6, 2026. Its latest daily candle is a hammer. Price is below its 50-day and below its 200-day moving average. RSI(14) 37, RS Rating 99, -47.0% from its 52-week high, +123.2% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
SLS technical analysis
Trend
SLS's moving averages are mixed — no clean uptrend or downtrend. It closed 27.2% below the 50-day ($11.56) and 3.1% below the 200-day ($8.68). ADX(14) at 21 points to a moderate trend. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 37, in the bearish half of its range. MACD crossed below its signal line 6 sessions ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 1.0× its 20-day average. It trades about $81.4M a day on average. ATR(14) is $1.02, 12.1% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.13) shows distribution.
Key levels
The 52-week range is $1.39 to $15.88; price is 47.0% below the high and 505.4% above the low. The VWAP anchored at the 52-week high is $12.17, above price.
Performance
SLS returned -13.1% (1 week), -25.3% (1 month), -23.8% (3 months), +68.0% (6 months), +400.9% (1 year), +123.2% (year to date).
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Pharmaceutical Preparations · Listed 2008 · 13 employees
Insider activity
SEC Form 4 transactions in SLS
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Stergiou Angelos M. President and CEO · Common Stock · 2026-06-16 | Grant | 1.06M | — | 2026-06-16 | 2026-06-18 |
SEC filings
EDGAR filings in SLS · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.